(Q34736674)

English

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

0 references

peritoneal dialysis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

hemodialysis patient

1 reference

based on heuristic

inferred from title

author name string

Knupp CA

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Hak LJ

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Coakley DF

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Falk RJ

4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Wagner BE

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Raasch RH

6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

van der Horst CM

7

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Kaul S

8

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Barbhaiya RH

9

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Dukes GE

10

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

language of work or name

0 references

publication date

1 November 1996

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

60

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

535-542

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

21 January 2018

Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

21 January 2018

Metabolism of 2',3'-dideoxyinosine (ddI) in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

21 January 2018

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

The assessment of fractional drug removal by extracorporeal dialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

Metabolism of 14C-2',3'-dideoxyinosine by the in situ perfused rat liver preparation

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

Purine metabolism in women with primary gout

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990149-6

7 January 2021

Identifiers

10.1016/S0009-9236(96)90149-6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34736674&oldid=2165221603"